Eledon Pharmaceuticals Inc
$ 2.42
-2.02%
26 Feb - close price
- Market Cap 196,687,000 USD
- Current Price $ 2.42
- High / Low $ 2.53 / 2.36
- Stock P/E N/A
- Book Value 1.52
- EPS -1.30
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.44 %
- ROE -0.95 %
- 52 Week High 4.60
- 52 Week Low 1.35
About
Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral sclerosis (ALS) who require organ or cell transplantation. The company is headquartered in Irvine, California.
Analyst Target Price
$8.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-14 | 2025-05-07 | 2025-03-26 | 2024-11-07 | 2024-08-19 | 2024-06-20 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -0.21 | -0.13 | -0.08 | -0.9456 | -0.32 | -1.06 | -0.34 | -0.29 | -0.35 | -0.4 | -0.75 | -0.69 |
| Estimated EPS | -0.2414 | -0.22 | -0.3033 | -0.3267 | -0.31 | -0.3 | -0.37 | -0.39 | -0.46 | -0.46 | -0.6 | -0.7 |
| Surprise | 0.0314 | 0.09 | 0.2233 | -0.6189 | -0.01 | -0.76 | 0.03 | 0.1 | 0.11 | 0.06 | -0.15 | 0.01 |
| Surprise Percentage | 13.0075% | 40.9091% | 73.6235% | -189.4399% | -3.2258% | -253.3333% | 8.1081% | 25.641% | 23.913% | 13.0435% | -25% | 1.4286% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.2 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELDN
2026-02-14 13:27:35
Eledon Pharmaceuticals discussed data from its Phase II BESTOW kidney transplant study, highlighting notable safety advantages for its investigational immunosuppressive therapy, "tego," despite not meeting the primary kidney-function endpoint. The company plans to request an end-of-Phase II FDA meeting soon and aims to start a registrational Phase III study by year-end, focusing on a composite non-inferiority endpoint and patient-reported quality-of-life measures. Eledon also provided updates on its islet cell transplant program and xenotransplant collaborations, affirming a cash runway through Q2 2027 to support its development activities.
2026-02-06 16:19:25
Eledon Pharmaceuticals announced that its President and Chief Scientific Officer, Steven Perrin, Ph.D., will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. The event is scheduled for February 12, 2026, at 10:00 a.m. ET. Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies, with its lead product being tegoprubart.
2026-02-06 14:57:58
Eledon Pharmaceuticals, Inc. announced that its President and Chief Scientific Officer, Steven Perrin, Ph.D., will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:00 a.m. ET. The company is a clinical-stage biotechnology firm developing immune-modulating therapies, with its lead product, tegoprubart, an anti-CD40L antibody, being investigated for various transplantation indications and amyotrophic lateral sclerosis (ALS).
2026-02-05 21:29:12
Eledon Pharmaceuticals announced that Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. The event is scheduled for Thursday, February 12, 2026, at 10:00 a.m. ET. Eledon Pharmaceuticals is a clinical stage biotechnology company focused on developing immune-modulating therapies, with its lead investigational product being tegoprubart.
2026-02-05 21:28:50
Eledon Pharmaceuticals announced that its President and Chief Scientific Officer, Steven Perrin, Ph.D., will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. The company, a clinical-stage biotechnology firm, is developing immune-modulating therapies, with its lead product being tegoprubart, an anti-CD40L antibody. Eledon is conducting preclinical and clinical studies for various conditions including kidney allograft transplantation and amyotrophic lateral sclerosis (ALS).
2026-02-05 14:57:58
Eledon Pharmaceuticals (NASDAQ: ELDN) has received a consensus "Hold" rating from brokerages, based on recommendations from five analysts. The average 1-year target price for the stock is $9.67, with individual ratings ranging from sell to buy. Institutional investors have shown increased interest, with several funds boosting their stakes in the company.
